CEO Shawn Singh outlined the company’s progress on its lead clinical programs, particularly fasedienol, which is being developed for the acute treatment of social anxiety disorder (SAD). Singh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback